---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000111"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:45:53.746036+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones

## Summary
- Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.
- CAMP4 receives $17.5M upfront; eligible for up to $440M in milestone payments plus tiered royalties.
- CAMP4 performs research to identify and deliver lead ASO series; GSK responsible for development and commercialization.
- Tiered royalties on annual net sales range from low- to mid-single digits; royalty term per product defined.

## SEC filing metadata
- accession: 0001736730-25-000111
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/0001736730-25-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/camp-20251217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000111
- JSON: https://secwatch.observer/filing/0001736730-25-000111.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000111.txt

## Key facts
- Material Agreements
  Camp4 Therapeutics Corp entered into Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited valued at $17.5 million (effective 2025-12-17).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: GlaxoSmithKline Intellectual Property (No. 3) Limited
  - Value: $17.5 million
  - Effective: 2025-12-17
  source text: On December 17, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Research, Collaboration and License Agreement (the “Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/0001736730-25-000111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.